**Author details**

Stephen Soloway1,2

1 Arthritis and Rheumatology Associates of South Jersey, P.C., Vineland, NJ, USA

2 Chief of Rheumatology, Inspira Medical Network, Mullica Hill and Vineland, NJ, USA

\*Address all correspondence to: cdipaola@drsoloway.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**13**

*Don't Miss Lupus*

**References**

– 5th ed.

*DOI: http://dx.doi.org/10.5772/intechopen.96892*

[1] Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The Diagnosis and Treatment of Systemic Lupus Erythematosus. Dtsch Arztebl Int. 2015 Jun 19;112(25):423-32. doi: 10.3238/arztebl.2015.0423. PMID: 26179016; PMCID: PMC4558874.

manifestation of lupus nephritis. Saudi J Kidney Dis Transpl. 2018 Mar-Apr;29(2):443-451. doi: 10.4103/1319-

[8] Rutgers A, Sanders JS, Stegeman CA,

necrotizing glomerulonephritis. Rheum Dis Clin North Am. 2010 Aug;36(3): 559-572. doi: 10.1016/j.rdc.2010.05.002.

2442.229293. PMID: 29657218.

Kallenberg CG. Pauci-immune

[9] DeVrieze BW, Hurley JA. Goodpasture Syndrome. 2020 Mar 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–.

[10] Mustaqeem R, Arif A. Renal Tubular Acidosis. 2020 Aug 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–.

[11] Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J

Kidney Dis 2014;64:558-566.

[12] Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 2020;31:

[13] Huong DL, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine

[14] Yu F, Wu L-H, Tan Y, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney

[15] Cortazar FB, Stone JH. IgG4-related disease and the kidney. Nat Rev Nephrol

(Baltimore) 1999;78:148-166.

Int 2010;77:820-829.

2015;11:599-609.

PMID: 20688250.

PMID: 29083697.

PMID: 30085586.

435-446.

[2] Wallace, Daniel J. (Daniel Jeffrey), 1949-The lupus book : a guide for patients and their families / Daniel J. Wallace.

[3] Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane

Database Syst Rev. 2018 Jun

PMCID: PMC6513226.

29;6(6):CD002922. doi: 10.1002/14651858. CD002922.pub4. PMID: 29957821;

[4] Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019 May 8;13:1535- 1543. doi: 10.2147/DDDT.S170969. PMID: 31190735; PMCID: PMC6514126.

[5] Baigrie D, Bansal P, Goyal A, Crane JS. Leukocytoclastic Vasculitis. 2020 Aug 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls

Publishing; 2020 Jan–. PMID: 29489227.

[6] Qiao W, Ding H, Zuo Y, Jiang L, Zhou J, Han X, Yu L, Du R, M Hedrich C, Deng GM. Lupus IgG deposition causes arthritis but inhibits bone destruction through competitive occupation of FcγRI and reduced RANKL signalling. Clin Transl Immunology. 2020 Sep 6;9(9):e1174. doi: 10.1002/cti2.1174. PMID: 32994999;

[7] Komolafe OO. Rapidly progressive glomerulonephritis: A wild card

PMCID: PMC7507387.
